All Patients Improve, 50% Achieve 12-Week BED Remission
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The company plans to evaluate a shorter infusion period in the next cohort, with results expected in the future, which could enhance treatment efficiency and scalability. CEO Jason Carroll highlighted the importance of these results, particularly given the chronic nature of the patient population and the FDA's recent guidance on psychedelic treatments.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Appendix 4E and 2026 Annual Report
- Investor Webinar Presentation
- Appendix 4G and Corporate Governance Statement
- Entropy Advances TRP-8803 to US Phase 2 in Depression
- Application for quotation of securities - ENP
Later from Entropy Neurodynamics
- Notification of Date of 2026 AGM
- Notification regarding unquoted securities - ENP
- 2026 AGM Notice of Meeting, Letter of Access and Proxy
- TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study
- Cleansing Notice
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics